JNJ - Johnson & Johnson
145.99 0.00 (0.00%)
After hours: 5:24PM EST
| Previous Close | 144.50 |
| Open | 144.71 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 144.55 - 146.74 |
| 52 Week Range | 118.62 - 148.32 |
| Volume | 8,494,311 |
| Avg. Volume | 6,623,530 |
| Market Cap | 391.542B |
| Beta (3Y Monthly) | 0.31 |
| PE Ratio (TTM) | 256.57 |
| EPS (TTM) | 0.57 |
| Earnings Date | Jan 22, 2019 |
| Forward Dividend & Yield | 3.60 (2.47%) |
| Ex-Dividend Date | 2018-11-26 |
| 1y Target Est | 147.06 |
- GuruFocus.com•2 hours ago
Johnson & Johnson (JNJ) Chairman, CEO Alex Gorsky Sold $38.6 million of Shares
Chairman, CEO of Johnson & Johnson (NYSE:JNJ) Alex Gorsky sold 264,465 shares of JNJ on 11/16/2018 at an average price of $145.96 a share.
Market Realist•7 hours agoHow Bausch + Lomb/International Performed
Bausch + Lomb/International is a wholly owned subsidiary of Bausch Health Companies (BHC). Bausch + Lomb/International generated revenues of $1.1 billion in the third quarter of this year compared to $1.2 billion in the third quarter of 2017, reflecting a ~7% YoY decline. However, Bausch + Lomb/International witnessed ~3% organic revenue growth.
- Market Realist•10 hours ago
Analyzing Baxter International’s Operational Performance
Baxter International’s (BAX) cost of sales decreased from $1.58 billion in the third quarter of 2017 to $1.53 billion in the third quarter. The company’s gross profit increased from $1.13 billion in the third quarter of 2017 to $1.24 billion in the third quarter due to the favorable product mix and manufacturing efficiencies.
Market Realist•10 hours agoBaxter International: Why Investors Are Interested
Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018. In this series, we’ll discuss Baxter International’s financials, analysts’ views on the stock, valuation metrics, and geographic performance. The company’s business units include renal care, medication delivery, pharmaceuticals, clinical nutrition, advanced surgery, and acute therapies.
Reuters•15 hours agoNew jury fails to reach verdict in J&J South Carolina talc cancer trial
The case of Bertila Boyd-Bostic, who died of a rare form of cancer in 2017 at the age of 30, is the latest in a series of trials in the United States that centre around allegations that the company's talc-based powder contains cancer-causing asbestos. In May, a deadlocked jury at the Darlington County Court of Common Pleas in Charleston failed to reach a verdict in the first trial. J&J, which denies the allegations, to date has lost two trials and won three in the litigation over whether Johnson's Baby Powder causes mesothelioma, a tissue cancer closely linked to asbestos exposure.
- PR Newswire•15 hours ago
ACUVUE OASYS with Transitions Light Intelligent Technology Named Among TIME's 'Best Inventions of 2018'
First-of-its-kind contact lens corrects vision and adapts to changing light conditions JACKSONVILLE, Fla. , Nov. 16, 2018 /PRNewswire/ -- TIME has selected ACUVUE OASYS with Transitions Light Intelligent ...
Reuters•yesterdayNew jury fails to reach verdict in J&J South Carolina talc cancer trial
The case of Bertila Boyd-Bostic, who died of a rare form of cancer in 2017 at the age of 30, is the latest in a series of trials in the United States that center around allegations that the company's talc-based powder contains cancer-causing asbestos. In May, a deadlocked jury at the Darlington County Court of Common Pleas in Charleston failed to reach a verdict in the first trial. J&J, which denies the allegations, to date has lost two trials and won three in the litigation over whether Johnson's Baby Powder causes mesothelioma, a tissue cancer closely linked to asbestos exposure.
- Zacks•2 days ago
Johnson & Johnson (JNJ) Up 3.4% Since Last Earnings Report: Can It Continue?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Motley Fool•2 days agoWhy Johnson & Johnson's Up 3% So Far in 2018
Here's what's keeping the healthcare giant in check.
- Simply Wall St.•2 days ago
Should You Be Pleased About The CEO Pay At Johnson & Johnson’s (NYSE:JNJ)
Alex Gorsky became the CEO of Johnson & Johnson (NYSE:JNJ) in 2012. First, this article will compare CEO compensation with compensation at other large companies. Next, we’ll consider growth that Read More...
Market Realist•2 days agoWhy Wall Street Is Still Bullish on Tandem Stock
This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating. The mean rating for Tandem Diabetes Care stock is 2.1 with a price target of $52.8, implying an upside potential of 65% over the closing price of $32.0 on November 13.
Reuters•2 days agoJury clears J&J of liability in California talc cancer case
The jury in Humboldt County Superior Court in Eureka, California rejected claims by Carla Allen who said that her mesothelioma, a tissue cancer closely linked to asbestos exposure, was caused by the company's talc products, including Johnson's Baby Powder. J&J denies the allegations, saying decades of scientific testing and regulatory approvals have shown its talc to be safe and asbestos-free.
- Reuters•2 days ago
Jury clears J&J of liability in California talc cancer case
The jury in Humboldt County Superior Court in Eureka, California rejected claims by Carla Allen who said that her mesothelioma, a tissue cancer closely linked to asbestos exposure, was caused by the company's talc products, including Johnson's Baby Powder. J&J denies the allegations, saying decades of scientific testing and regulatory approvals have shown its talc to be safe and asbestos-free.
- Zacks•2 days ago
AbbVie's HCV Drug Mavyret Succeeds in Label Expansion Study
AbbVie's (ABBV) Mavyret demonstrates high virologic cure rates in a study evaluating it for an expanded patient population.
Market Realist•2 days agoTandem Diabetes Care’s Operational Performance
For fiscal 2018 and 2019, Tandem Diabetes Care’s gross margins are expected at 47.13% and 51.78%, respectively, compared with 40% in fiscal 2017. The fiscal 2018 gross margins of peers DexCom (DXCM), Insulet (PODD), and Johnson & Johnson (JNJ) are expected at 64.29%, 65.59%, and 70.43%, respectively. Tandem Diabetes Care incurred selling, general, and administrative expenses of $29.51 million in the third quarter of 2018, versus $20.12 million in the third quarter of 2017.
Market Realist•2 days agoWhy Tandem Should Be on Your Stock Radar
Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on pumps’ home screens. This is the only pump capable of remote feature updates on the US market. Tandem also sells disposable products such as cartridges and infusion sets that are used with its pumps and replaced periodically. In August 2018, Tandem began the commercialization of the t:slim X2 in key regions outside the United States.
- MarketWatch•2 days ago
Here’s how to easily reduce your investment risk just at the right time
Mike Loewengart of E-Trade discusses equal-weighted and bond ETFs, and actively managed funds for diversification.
Market Realist•3 days agoGauging Analysts’ Views on TransEnterix Stock
In November, of the five analysts covering TransEnterix (TRXC), three have given it “buy” or higher ratings, and two have given it “hold” ratings.
- Financial Times•3 days ago
[$$] The Theranos tale exposes the dangers lurking in Silicon Valley
At some point, probably next year, Elizabeth Holmes, the charismatic founder of Theranos, and her ex-boyfriend Ramesh “Sunny” Balwani, the group’s former chief operating officer, will stand trial, charged with defrauding investors, doctors and patients. Somewhere among the court reporters will be investigative journalist John Carreyrou, completing an assignment that started in February 2015 when he received a tip about Ms Holmes, a Silicon Valley prodigy promising to shake up healthcare with a revolutionary blood-testing system. , his first book, which chronicles the rise and fall of Theranos.
- Motley Fool•3 days ago
3 Top Healthcare Stocks to Buy in November
An insurer, a medical device company, and a healthcare Goliath could all be smart additions to portfolios this month.
Market Realist•3 days agoUnderstanding TransEnterix’s Operational Performance
For 2018 and 2019, TransEnterix’s gross margins are expected to be 41.40% and 48.76%, respectively, compared to its gross margin of 5.4% in 2017. In comparison, the 2018 gross margins of its peers Intuitive Surgical (ISRG), Johnson & Johnson (JNJ), and Stryker (SYK) are expected to be 71.01%, 70.43%, and 66.29%, respectively. TransEnterix incurred general and administrative expenses of $3.69 million in the third quarter compared to $2.92 million in the third quarter of 2017 primarily due to higher personnel costs and outsourced services expenses.
Market Realist•3 days agoHow TransEnterix Has Been Performing in November
TransEnterix (TRXC) is a medical device company focused on digitizing the interface between surgeons and patients for the improvement of minimally invasive surgery. TransEnterix’s Senhance surgical system digitizes laparoscopic minimally invasive surgery and allows for robotic precision, haptic feedback, surgeon camera control, and improved ergonomics. TransEnterix generated total revenue of $5.42 million in the third quarter compared to $183,000 in the comparable period of 2017.
Markit•4 days agoSee what the IHS Markit Score report has to say about Johnson & Johnson.
Johnson & Johnson NYSE:JNJ
- Zacks•4 days ago
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
Johnson & Johnson (JNJ) closed at $145.62 in the latest trading session, marking a +0.19% move from the prior day.
- Motley Fool•4 days ago
Stock Market Power Rankings: Last Call for Facebook
They're big, beautiful, and ranked from 1 to 50.
